Zebrafish research tests safer, less toxic cancer therapies

April 17, 2015
Zebrafish research tests safer, less toxic cancer therapies
Dalhousie Medical School researchers have successfully been able transplant human leukemia cells into zebrafish embryos (shown above) to study their growth and test anti-cancer therapies. Credit: Nick Pearce photo

Two new cancer studies out of Dalhousie Medical School have shown success in testing safer, less toxic treatments for a rare form of pediatric leukemia called T-cell acute lymphocytic leukemia (T-ALL). The studies were published by first-year medical student, Victoria Bentley, and Drs. Graham Dellaire and Jason Berman, associate professors in the Departments of Pathology and Pediatrics, respectively.

"There are about 300 cases of childhood in Canada each year," says Dr. Dellaire. "80 per cent of those are (ALL). T-ALL—specifically targets our body's T-cells and accounts for approximately 15 per cent of these cases."

"The studies are important because T-ALL is a high risk subset of leukemia that needs better therapies with less toxicities," says Bentley. "We need better ways to screen drugs before they enter clinical trials and better ways to design a patient's treatment plan. It's possible to do both with the zebrafish xenotransplant model."

The first study, published in Haematologica, demonstrates for the first time that T-cell leukemia from a patient's bone marrow can be successfully xenografted—where tissues of one species are transplanted to another—in zebrafish.

The process involves microinjecting a patient's tumor cells into the yolk sac of a 48-hour-old zebrafish embryo. As the zebrafish continues its natural growth, the T-ALL cells engraft in the zebrafish, allowing treatment response to be tested in the lab. An effective drug is identified when the xenografted cells in the zebrafish no longer divide—or ultimately die—compared to cells without a drug treatment.

"Our zebrafish xenograft model allowed us to determine the susceptibility of a patient's T-ALL within three days," says Dr. Dellaire. "If we were using this information to guide therapy, we could rapidly identify an effective drug and personalize a patient's therapy, reducing side-effects and improving outcome."

The co-authors are also using a to test protectants for cardiotoxicity: the damaging effects of chemotherapy on the heart.

Published in Science Translational Medicine, the group's second, high-impact study examined the chemotherapy drug doxorubicin, a common treatment for leukemias and many adult cancers, including breast cancer.

"When zebrafish embryos are treated in water with doxorubicin, they develop abnormalities of the heart," explains Dr. Berman. "Children treated with doxorubicin for leukemia often suffer heart damage, predisposing them to heart failure for many years following treatment."

The group's studies on chemoprotectants began through a collaboration with Dr. Randall Peterson at Massachusetts General Hospital and Harvard Medical School. The group identified a number of compounds that protects the heart against doxorubicin, the most promising being a drug called visnagin.

It was discovered that when visnagin was used in the group's leukemia zebrafish transplant model, the doxorubicin treatment retained it's ability to effectively kill the human cells xenografted in the zebrafish, but the visnagin prevented damage to the zebrafish heart.

"Clearly, if doxorubicin-like drugs are going to continue to be used, we need to be able to give these safely," says Dr. Berman. "Identifying new heart protective drugs is really important. Ultimately, drugs like visnagin may be combined with chemotherapy given to patients. The combination isn't planned for clinical trial yet, but is something that we hope to pursue in the future."

Explore further: Targeting mitochondrial enzyme may reduce chemotherapy drug's cardiac side effects

More information: "Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase." Sci Transl Med 10 December 2014: Vol. 6, Issue 266, p. 266ra170 DOI: 10.1126/scitranslmed.3010189

Related Stories

Targeting mitochondrial enzyme may reduce chemotherapy drug's cardiac side effects

December 10, 2014
Massachusetts General Hospital (MGH) investigators have identified two compounds that appear, in cellular and animal models, to block the cardiac damage caused by the important chemotherapy drug doxorubicin. Their report ...

Common mutation is culprit in acute leukemia relapse

March 6, 2014
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patient care strategies ...

Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment

April 9, 2012
A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans – even ...

Promising drug a 'new paradigm' for treating leukemia

March 25, 2015
Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved ...

New molecule protects heart from toxic breast cancer drugs

February 3, 2015
A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumor. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is ...

Zebrafish models identify high-risk genetic features in leukemia patients

May 10, 2011
Leukemia is the most common childhood cancer; it also occurs in adults. Now researchers working with zebrafish at Huntsman Cancer Institute (HCI) at the University of Utah have identified previously undiscovered high-risk ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.